1,639 reports of this reaction
4.0% of all SOFOSBUVIR reports
#4 most reported adverse reaction
HEADACHE is the #4 most commonly reported adverse reaction for SOFOSBUVIR, manufactured by Gilead Sciences, Inc.. There are 1,639 FDA adverse event reports linking SOFOSBUVIR to HEADACHE. This represents approximately 4.0% of all 41,429 adverse event reports for this drug.
Patients taking SOFOSBUVIR who experience headache should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
HEADACHE is moderately reported among SOFOSBUVIR users, representing a notable but not dominant share of adverse events.
In addition to headache, the following adverse reactions have been reported for SOFOSBUVIR:
The following drugs have also been linked to headache in FDA adverse event reports:
HEADACHE has been reported as an adverse event in 1,639 FDA reports for SOFOSBUVIR. This does not prove causation, but indicates an association observed in post-market surveillance data.
HEADACHE accounts for approximately 4.0% of all adverse event reports for SOFOSBUVIR, making it a notable side effect.
If you experience headache while taking SOFOSBUVIR, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.